Straits Times Index
3,159.92 -27.74 (-0.87%) Nikkei
36,815.50 -1,264.20 (-3.32%) Hang Seng
16,119.87 -266.00 (-1.62%) FTSE 100
7,877.05 +29.06 (+0.37%) Bitcoin USD
60,068.19 -1,608.09 (-2.61%) CMC Crypto 200
1,243.13 +357.60 (+37.49%)
VRTX Jun 2024 200.000 put
| Previous close | 0.8500 |
| Open | 0.8500 |
| Bid | 0.0000 |
| Ask | 2.2500 |
| Strike | 200.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.8500 - 0.8500 |
| Contract range | N/A |
| Volume | |
| Open interest | 59 |
Business WireVertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
BOSTON, April 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548).
ZacksVertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Vertex Pharmaceuticals (VRTX) closed at $394.17 in the latest trading session, marking a -0.8% move from the prior day.
Associated Press FinanceVertex Pharma scientist talks about the long road to developing non-addictive painkillers
For decades, patients seeking medication for pain have had two choices: over-the-counter drugs like aspirin or powerful prescription opioids like oxycodone. Opioid prescriptions have plummeted over the last decade as doctors have become more attuned to the risks of addiction and misuse during the country’s ongoing drug epidemic. Vertex Pharmaceuticals recently reported positive results for a non-opioid painkiller, one of several medications the Boston-based drugmaker has been developing for various forms of pain.
